Want to read Slashdot from your mobile device? Point it at m.slashdot.org and keep reading!


Forgot your password?

Submission + - Approval for Drug to Treat Type of Leukemia (bloomberg.com)

DevotedSkeptic writes: "Pfizer Inc. (PFE), the world’s largest drugmaker, won U.S. regulatory approval of its treatment for one of the four most common types of leukemia.

The Food and Drug Administration cleared the drug, to be known as Bosulif, for adults with previously treated chronic myeloid leukemia who also have an abnormality known as the Philadelphia chromosome, the New York-based company said today in a statement. There are expected to be about 5,400 new cases and 610 deaths from the blood cancer this year, according to the American Cancer Society in Atlanta.

Bosulif will compete with Novartis AG (NOVN)’s Tasigna and Bristol-Myers Squibb Co. (BMY)’s Sprycel. Pfizer’s treatment is expected to generate $171 million in sales in 2015, according to the average estimate of six analysts compiled by Bloomberg.

“Bosulif is an important new addition to the CML treatment landscape,” Jorge Cortes, a professor of medicine at the University of Texas MD Anderson Cancer Center, and a lead investigator of the Pfizer-sponsored study on the drug, said in the company’s statement. “Despite recent advances, an unmet need remains.”

Treatment is improving based on a better understanding of the molecular basis of the disease, Richard Pazdur, director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research, said in a statement from the agency. The FDA designated Bosulif as an orphan drug, meaning it treats a disease that affects fewer than 200,000 people. Bosulif is chemically known as bosutinib."

This discussion was created for logged-in users only, but now has been archived. No new comments can be posted.

Approval for Drug to Treat Type of Leukemia

Comments Filter:

"Let every man teach his son, teach his daughter, that labor is honorable." -- Robert G. Ingersoll